Clinical trials: Transient Ischemic Attacks
Transient Ischemic Attack
Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack
It is hypothesized that the addition of formal cardiac rehabilitation to standard care will result in long-term improvements in cardiovascular fitness and functional capacity in individuals who have suffered a transient ischemic…
- Trial name
- NCT00929994
- Testing
- Cardiac Rehabilitation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Toronto Rehabilitation Institute
Vertebrobasilar Insufficiency, Ischemic Attack, Transient
Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Patients with blockage of the blood vessels that supply blood to the back of the brain, known as vertebrobasilar disease (VBD), are at risk of having a stroke or temporary symptoms of a stroke known as transient ischemic attack…
- Conditions
- Vertebrobasilar Insufficiency, Ischemic Attack, Transient, Cerebrovascular Disorder, Brain Ischemia
- Trial name
- VERiTAS (NCT00590980)
- Where
- 6 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- University of Illinois at Chicago
Ischemic Stroke, Intracranial Hemorrhage
Stroke Education Intervention Trial - Pilot
The objectives of the trial of a medication-coach program for patients with stroke or transient ischemic attack are to pilot test the study design, the intervention components and the data collection forms and refine them for a…
- Conditions
- Ischemic Stroke, Intracranial Hemorrhage, Transient Ischemic Attack
- Trial name
- AVAIL II (NCT01115660)
- Testing
- stroke education
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Transient Ischemic Attack, Stroke
Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
This program will seek to implement a quality improvement program to improve the care of Veterans with TIA or minor stroke at 6 Veteran Health Administration Hospitals.
- Trial name
- PREVENT (NCT02769338)
- Testing
- Quality Improvement Program
- Where
- United States
- Volunteers
- 2,292 people
- Sponsor
- VA Office of Research and Development
Stroke Recurrence, Transient Ischemic Attack
Prevent Return of Stroke Study
The purpose of this study is to evaluate if a peer-led stroke recurrence prevention intervention, versus usual care, will help reduce risk factors for recurrent strokes among adults in Harlem.
- Trial name
- NCT01027273
- Testing
- Prevent Return of Stroke
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Stroke
Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
The purpose of this multicenter study is to investigate the extra-/intra-cranial atherosclerosis distribution pattern in chinese populations with transient ischemic attack and ischemic stroke and analyze the influencing factors…
- Trial name
- NCT02397655
- Where
- China
- Volunteers
- 12,012 people
- Sponsor
- Xuanwu Hospital, Beijing
Stroke, Transient Ischemic Attack
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk…
- Trial name
- REDUCE (NCT00738894)
- Testing
- Septal Occluder Device, Antiplatelet Medical Therapy
- Where
- 2 sites in United States, Denmark
- Volunteers
- 664 people
- Sponsor
- W.L.Gore & Associates
Atrial Fibrillation, Stroke
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm.
- Trial name
- NCT00129545
- Testing
- WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
- Where
- 62 sites in United States, Czechia and 1 more
- Volunteers
- 800 people
- Sponsor
- Boston Scientific Corporation
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take…
- Trial name
- CRYSTAL-AF (NCT00924638)
- Testing
- Reveal® XT Insertable Cardiac Monitor
- Where
- 55 sites in United States, Austria and 12 more
- Volunteers
- 447 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Stroke, Transient Ischemic Attack
Reducing Stroke Risk in African-American Men
The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs.
- Trial name
- TEAM2 (NCT04402125)
- Testing
- TargEted MAnageMent Intervention (TEAM)
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Case Western Reserve University
Ischaemic Attack, Transient
Safety Escalating Repeat IV, in Stroke Patients
The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
- Trial name
- MAG111539 (NCT00833989)
- Testing
- GSK249320
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Ischemic Stroke, Transient Ischemic Attack
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Rationale Acute ischemic stroke due to atrial fibrillation (AF) carries a high risk for early recurrence. In acute stage, guidelines recommend aspirin, but do not recommend anticoagulation due to the increased risk of…
- Trial name
- TripleAXEL (NCT02042534)
- Testing
- Rivaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 195 people
- Sponsor
- Asan Medical Center
Stroke, Ischemic Attack, Transient
Carotid Occlusion Surgery Study
The purpose of this study is to determine if extracranial-intracranial bypass surgery when added to best medical therapy can reduce the subsequent risk of ipsilateral stroke in high-risk patients with recently symptomatic carotid…
- Conditions
- Stroke, Ischemic Attack, Transient, Cerebral Infarction
- Trial name
- COSS (NCT00029146)
- Testing
- extracranial-intracranial bypass surgery, best medical therapy
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Stroke, Transient Ischemic Attack
Comprehensive Post-Acute Stroke Services
The purpose of this pragmatic study is to investigate whether implementation of a comprehensive post-acute stroke service model that integrates Early Supported Discharge (ESD) and Transitional Care Management (TCM) for stroke…
- Trial name
- COMPASS (NCT02588664)
- Testing
- COMPASS Intervention
- Where
- 40 sites in United States
- Volunteers
- 6,024 people
- Sponsor
- Wake Forest University Health Sciences
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.